Date: 2011-10-03
Type of information: Distribution agreement
Compound: 10 deCODE Genetics\' DNA-based tests for assessing the risk of developing certain common diseases.
Company: Warnex (Canada) Decode Genetics (Iceland)
Therapeutic area: Cancer Oncology Cardiovascular diseases Ophtalmological diseaes
Type agreement: distribution
Action mechanism:
Disease:
Details: Warnex Medical Laboratories, a division of Warnex Inc, and deCODE Genetics have signed an exclusive distribution agreement in Canada for 10 of deCODE Genetics\\\' DNA-based tests for assessing the risk of developing certain common diseases.
Warnex will offer the following DNA-based risk assessment tests:
- deCODE ProstateCancer® (The test detects 27 genetic variants associated with risk of prostate cancer in males of European descent and which have been shown to have significant impacts on a man\\\'s assessed lifetime risk. For African-Americans and East Asians, the test detects 9 and 12 genetic variants, respectively, that associate with risk of prostate cancer).
- deCODE MI® (The test detects 8 SNPs in the sequence of the genome associated with risk of heart attack. These include the chromosome 9p21 variants discovered by deCODE, the highest impact and best validated genetic risk factors for heart attack yet found. The test provides a novel means of detecting the substantial genetic component to overall susceptibility to heart attack, risk that appears to be independent of well known risk factors such as elevated cholesterol and hypertension.)
- deCODE AF® (This test assesses the risk of atrial fibrillation (AF). In-patient post-stroke cardiac monitoring misses a large proportion of intermittent AF. This test enables physicians to target and personalize the use of ambulatory cardiac monitoring and optimize stroke prevention in those found to have AF).
- deCODE Clopidogrel® (The test identifies patients who may need adjustment of their Clopidogrel dose or who should be put on an alternative medication to prevent recurrent adverse cardiovascular events. The test analyzes 5 SNPs in the CYP2C19 gene that affect response to the anti-platelet drug Clopidogrel.)
- deCODE BreastCancer® (The test detects 16 genetic risk factors for the common forms of breast cancer. The common forms of the disease account for approximately 95% of all breast cancers.)
- deCODE T2® (The test assesses the risk of type 2 diabetes independent of family history and obesity. The test detects DNA markers that have been widely replicated as risk factors for type 2 diabetes. The deCODE TCF7L2 marker is the strongest genetic risk factor discovered so far for type 2 diabetes and has been validated in over 40 populations and multiple continental ancestries.)
deCODE Glaucoma® (The test assesses the risk of exfoliation glaucoma. The test detects two SNP markers associated with increased risk of exfoliation glaucoma. They are located in a gene called LOXL1, and about 10-30% of all primary open angle glaucoma patients have the at-risk versions of these SNPs in the LOXL1 gene.)
- deCODE Cancer (This DNA-based test panel measures risk for 7 common cancers: colon, lung, bladder, thyroid and basal cell carcinoma, as well as breast and ovarian cancer in women and prostate and testicular cancer in men.)
- deCODE Cardiovascular (The test assesses the risk of 6 cardiovascular diseases including myocardial infarction, type 2 diabetes, atrial fibrillation, abdominal aortic aneurysm, intracranial aneurysm and venous thromboembolism, as well as clopidogrel responsiveness.)
- deCODE Complete (The test analyzes risk factors for more than 45 common diseases and traits, including all of the aforementioned individual tests. This scan focuses on medical conditions that can either be prevented through altered lifestyle or have better treatment outcomes if detected early.)
Financial terms:
Latest news:
